Stockreport
Incyte's Pipeline Potential Signals Massive Upside For Investors [Seeking Alpha]
Last incyte corporation earnings: 2/13 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations: incyte.com/ir/investor-overview.aspx
INCY's non-Jakafi portfolio is rapidly expanding, with Opzelura and oncology assets driving double-digit growth and significant margin improvement. Management targets 15–20% five-year sales CAGR and $3–4B ex-Jakafi revenue by 2030, diverging from consensus' negative growth view. Upcoming catalysts include the mid-2026 launch of Jakafi XR and potential approvals for Povorcitinib, providing a defensive bridge against the 2028 patent cliff. My valuation model implies 33% upside in 12 months, with execution on pipeline commercialization as the key risk. Looking for a helping hand in the market? Members of Beyond the Wall Investing get exclusive ideas and guidance to navigate any climate. Learn More » Liubomyr Vorona/iStock via Getty Images Buying Incyte on Strong Financials and Discounted Valuation Incyte Corporation INCY ) is a $19 billion market cap biotech company that offers a diverse pipeline of therapies for cancer, blood disorders, and dermatology. What's notable for
[Read more]
| IMPACT SNAPSHOT | EVENT TIME: | INCY | ||||
|---|---|---|---|---|---|---|
|
Last Price
|
Price Change
|
Price Change %
|
Volume Shares
|
Max Up
|
Max Down
|
Volume Ratio
%
|
Performance comparison
Updated
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| LAST PRICE | ||
| VWAP | ||
|
High:
|
MAX UP |
High:
|
|
Low:
|
MAX DOWN |
Low:
|
|
%
|
POST NEWS RANGE |
%
|
|
|
PRICE CHANGE |
|
|
|
PRICE CHANGE PERCENTAGE |
|
|
|
S&P 500 (SPX) |
|
|
%
|
VOLUME RATIO |
%
|
| VOLUME (SHARES) | ||
| TICKS | ||
|
|
AVG SHARES PER TRADE |
|
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Be the first to know
Opt in for alerts from News Quantifed
Opt-in for
INCY alerts
INCY alerts
from News Quantified
Movers & Shakers
The biggest gainers and losers and WHY it moved
INCY alerts
High impacting Incyte Corporation news events
Weekly update
A roundup of the hottest topics
INCY
NEWS
NEWS
- Incyte: Buy For The Turnaround, Stay For The Pipeline [Seeking Alpha][Seeking Alpha]
- Factbox-Pharma sector doubles down on AI amid hopes of slashing costs, timelines [Yahoo! Finance][Yahoo! Finance]
- Earnings Preview: What To Expect From Incyte's Report [Yahoo! Finance][Yahoo! Finance]
- Why Incyte (INCY) Stock Is Trading Up Today [Yahoo! Finance][Yahoo! Finance]
- Incyte CEO Bill Meury: Blood cancer therapy development is company's central identity [CNBC][CNBC]
- More
INCY
SEC Filings
SEC Filings
- 1/8/26 - Form 4
- 1/7/26 - Form 4
- 1/7/26 - Form 144
- INCY's page on the SEC website
- More